Sanofi trial failure ends development of breast cancer treatment amcenestrant

Sanofi stopped further work on amcenestrant, once seen to have large potential against breast cancer, after a second trial failure dealt a major blow to the French healthcare company’s development prospects. The move weighed on shares and put more pressure on Sanofi to bolster its pipeline of drug candidates as it becomes increasingly dependent on […]